|Company||Reliance Pharmaceuticals Ltd.|
Adult: PO Resp tract infections; Skin and soft tissue infections 500 mg once daily for 3 days. Chancroid; Non-gonococcal cervicitis/urethritis due to Chlamydia trachomatis; Uncomplicated genital infections due to Chlamydia trachomatis 1 g as a single dose.
Prophylaxis of disseminated MAC infections 1.2 g once wkly. Treatment or secondary propjhylaxis: 500 mg once daily w/ other antimycobacterials.
Uncomplicated gonorrhoea 2 g as a single dose. Granuloma inguinale Initial: 1 g, then 500 mg/day until all lesions have healed completely.
Active immunisation against typhoid fever caused by Salmonella typhi 1 g once daily for 5 days.
IV Community-acquired pneumonia 500 mg as a single IV daily dose for 2 days, then 500 mg single oral dose daily to complete 7-10 days of therapy.
Pelvic inflammatory disease 500 mg as a single IV daily dose for 1-2 days, then 250 mg single oral dose daily to complete a 7-day therapy.
Child: >6 mth 10 mg/kg; 15-25 kg: 200 mg; 26-35 kg: 300 mg; 36-45 kg: 400 mg. All doses to be taken once daily for 3 days.
Alternative Brands to AM
- Odazyth SR
- Azithrocin IV
- Rozith IV
- Soto A
- Azilab 500
- N Zith
- Azi-S 500
- Zimax IV
- Azitra 500
Bacterial infections, bacterial endocarditis, typhoid fever, community-acquired pneumonia, uncomplicated gonorrhea, streptococcal pharyngitis/tonsillitis, COPD, acute bacterial sinusitis, acute otitis media, uncomplicated UTI, Uncomplicated gonorrhea, PID, non-gonococcal urethritis, chancroid, acute salmonellosis, cervicitis, babesiosis, chlamydial infections, pelvic inflammatory disease, PID, traveler's diarrhea,
Known hypersensitivity to azithromycin, erythromycin, any macrolide or ketolide antibiotic. Coadministration w/ pimozide. History of cholestatic jaundice/hepatic dysfunction associated w/ prior use of azithromycin.
GI disturbances, visual impairment and irritation; deafness, dizziness, headache, fatigue, anorexia, paraesthesia, dysgeusia, nasal congestion, sinusitis, facial swelling, periocular swelling, pruritus, rash, urticaria, arthralgia, vaginitis; inj site pain, inflammation; decreased lymphocyte count and blood bicarbonate, increased eosinophil count, transaminase levels and/or alkaline phosphatase levels.
Potentially Fatal: Angioedema and cholestatic jaundice.
Increases serum concentrations of digoxin, ciclosporin, terfenadine, hexobarbital and phenytoin. Decreased rate of absorption w/ antacids containing aluminium and magnesium. Increased risk of ergot toxicity.
Potentially Fatal: Increased risk of cardiotoxicity w/ pimozide.
- Infections of the respiratory tract
- Bacterial infections
- Acute otitis media
- Acute bacterial sinusitis
- Chlamydial cervicitis
- Chlamydial urethritis
- Typhoid fever
- Community-acquired pneumonia
- Paratyphoid fever
- Bacterial endocarditis
- Streptococcal pharyngitis/tonsillitis
- Non-gonococcal urethritis
- Acute salmonellosis
- Chlamydial infections
- Pelvic inflammatory disease
- Group A Strep. infections
- Streptococcal pharyngitis
- Skin and soft tissue infections
- Upper and lower respiratory tract infections
- Pharyngitis and Tonsillitis
- Urinary tract infection
- Respiratory tract infections
- Acute Exacerbations of Chronic bronchitis
- Gonococcal urethritis
- Enteric fever
- Genitourinary tract infections
- Granuloma inguinale
- Q fever
- Cat scratch disease
- Middle ear infections (otitis media)
- Atypical pneumonia
- Throat infections
- Uncomplicated gonorrhoea
- Scrub typhus
- Traveller's diarrhea
- Cervicitis and salpingitis
- Mycoplasma pneumoniae
- Haemophilus influenzae type b infection
- Bacteraemic pneumonia
- Acute gonorrheal urethritis
May increase the risk of Torsades de pointes and fatal heart arrhythmias in patients w/ prolonged QT interval, low K or Mg blood levels, slow heart rate and medication treating abnormal heart rhythms. Impaired hepatic and renal function. Pregnancy and lactation. Monitoring Parameters Liver function tests, CBC w/ differential.
Mode of Action
Azithromycin is a semisynthetic azalide antibiotic. It blocks transpeptidation by binding to 50s ribosomal subunit of susceptible organisms and disrupting RNA-dependent protein synthesis at the chain elongation step.